Top 100 best selling brand medicine in the world (Chinese version 2015)

Source: Xianda data on April 20, 2016, firstword listed the top 100 best-selling brand drugs in the world in 2015 In 2015, the total sales of these 100 brand drugs reached 265 billion US dollars, of which the total sales generated by the top 10 exceeded 80 billion US dollars At present, the global sales of two franchised products (harvoni of Gilead company and Humira of EBV, adalimumab) are over 10 billion US dollars, and the sales of the first 14 drugs are over 5 billion US dollars Geely's harvoni and sovaldi exclusive sales of hepatitis C add up to $19 billion These two drugs accounted for 59% of Gilead's total revenue in 2015, while Humira's accounted for 61% of Aberdeen's total revenue in 2015 Harvoni is not only the best-selling drug on the current list, but also the latest one on the market Other "next generation" hepatitis C drugs, including sovaldi and iberville's viekirapak, fall into this category Among the top 100, there are many products developed and launched in the past few years, Including tecbidera (bioten, multiple sclerosis), bairituo (Bayer / Johnson, anticoagulation), eliquis (Squibb, anticoagulation), stribild (Gilead, AIDS), eylea (regeneron / Bayer, Germany, age-related maculopathy), invokana (Johnson, diabetes) and xtandi / mediation Company, prostate cancer) Many drug franchises are held globally by two or more companies The addition of its sales volume has achieved the performance of brand medicine For example: 8.7 billion US dollars for etanercept (Amgen / Pfizer), 4 billion US dollars for regeneron / Bayer, 3.6 billion US dollars for Lucentis (Roche / Novartis) and 8.3 billion US dollars for REMICADE (Johnson / Merck) Among the top 100 companies listed in the table, Johnson & Johnson has the most 9 In addition, Squibb, Novartis and Roche each have 8, Amgen 7 and Gilead 6 However, in terms of total sales, Gilead (US $29 billion), Roche (US $28 billion) and Johnson & Johnson (US $20 billion) are the most profitable companies Among the top 100 drugs, the tumor sector accounts for 52 billion US dollars, accounting for the largest proportion (20%), and the total sales volume of autoimmune disease drugs is 39 billion US dollars, accounting for 15% of the total 29 billion US dollars in diabetes, accounting for 11%, and 22 billion US dollars in hepatitis C, accounting for 8%.